New data on risk vs benefit for potent CAR-T cancer drugs

(Reuters) - A promising but risky new group of customized cancer drugs will be in focus this weekend at the annual meeting of the American Society of Hematology (ASH), where clinical trial results will help clarify their potential for doctors and investors.